Hospital
ST. Vincent Jennings Hospital, INC.
ST. Vincent Jennings Hospital, INC. was paid $4.33M by Medicaid between Jan 2018 and Nov 2024, across 61 billing codes. Its largest line is 99283, emergency room visit (moderate) — 38% of everything it billed.
33Billing provider infoST. VINCENT JENNINGS HOSPITAL, INC.
NORTH VERNON, IN 47265
NORTH VERNON, IN 47265
33aNPI1285684829assigned 05/12/2006
33bProvider typeCritical Access Hospital
28Total paid$4.33M
24GClaims119,894
24DCodes billed61
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Indiana
Rank by total paid#13 of 26
Median peer was paid$4.16M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,273 | $134K | |
| 2019 | 9,318 | $142K | |
| 2020 | 13,752 | $510K | |
| 2021 | 19,989 | $876K | |
| 2022 | 25,849 | $1.09M | |
| 2023 | 22,217 | $989K | |
| 2024incomplete | 14,496 | $583K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 38% | 10,779 | 9,429 | $1.63M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 8,140 | 6,388 | $859K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 4,051 | 3,336 | $392K |
| 71045 | Radiologic examination, chest; single view | 8.2% | 2,958 | 2,315 | $356K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.1% | 2,831 | 2,164 | $136K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.1% | 2,353 | 1,892 | $136K |
| 80053 | Comprehensive metabolic panel | 2.5% | 18,353 | 15,068 | $110K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 20,165 | 16,042 | $90K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 451 | 387 | $78K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.8% | 1,143 | 982 | $77K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 1,888 | 1,648 | $75K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 433 | 388 | $59K |
49 more codes
| 36415 | Collection of venous blood by venipuncture | <1% | 17,878 | $43K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,378 | $41K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 277 | $35K |
| 80061 | Lipid panel | <1% | 4,189 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 579 | $31K |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 3,857 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 695 | $13K |
| 87634 | <1% | 178 | $11K | |
| 84484 | <1% | 1,163 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,318 | $8K |
| 82607 | <1% | 836 | $8K | |
| 82746 | <1% | 824 | $7K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 109 | $7K |
| 81001 | <1% | 2,964 | $6K | |
| 83655 | <1% | 443 | $6K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 787 | $5K |
| 86803 | <1% | 451 | $5K | |
| 87081 | <1% | 744 | $5K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 57 | $4K |
| 71271 | <1% | 19 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 238 | $4K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 30 | $4K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 690 | $3K |
| 80306 | <1% | 308 | $3K | |
| 83540 | <1% | 555 | $2K | |
| 83690 | <1% | 502 | $2K | |
| 83605 | <1% | 267 | $2K | |
| 82728 | <1% | 138 | $1K | |
| 83550 | <1% | 192 | $1K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 94 | $829.84 |
| 82570 | <1% | 207 | $594.96 | |
| 82043 | <1% | 186 | $570.01 | |
| 81025 | <1% | 76 | $518.92 | |
| 83735 | <1% | 94 | $516.19 | |
| 84439 | <1% | 95 | $516.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 146 | $461.82 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 36 | $440.85 |
| 86140 | <1% | 153 | $423.34 | |
| 87088 | <1% | 71 | $288.09 | |
| 87070 | <1% | 29 | $232.74 | |
| 82553 | <1% | 114 | $189.12 | |
| 80076 | <1% | 37 | $184.71 | |
| 82550 | <1% | 112 | $183.03 | |
| 85610 | <1% | 47 | $115.83 | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 14 | $49.80 |
| 85652 | <1% | 30 | $26.29 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 13 | $0.00 |
| A9270 | Non-covered item or service | 0% | 97 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 32 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROCHE, JOSEPH (ADMINISTRATOR)
| Provider | Location | Paid |
|---|---|---|
| Dermatology Group of the Carolinas | Concord, NC | $1.85M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.